Type 1 Diabetes Grand Challenge - Novel Insulins Innovation Incubator

The Type 1 Diabetes Grand Challenge is a pioneering partnership between the Steve Morgan Foundation (SMF), JDRF and Diabetes UK that will work towards the shared goal of transforming the lives of people with type 1 diabetes and finding a cure for the condition.

The ‘Novel Insulins Innovation Incubator’ call is designed to drive transformational therapy development, so projects are sought that will advance concepts toward clinical development and delivery.

Priority given to high risk/high reward projects that have the potential to move the field in big steps, not incremental developments. It is not limited to a particular type of novel insulin. Applications investigating any bold concept, for example glucose responsive insulins, liver targeted insulins, monomeric/dimeric insulins etc. are equally welcome. Strong preliminary data should form the basis of any application.

It is expected that results will be published in peer-reviewed journals to benefit the broader scientific community. If the results warrant patenting, publication will be expected as soon as protection has been granted.

Funding:
£500,000 (up to £1 million may be considered uder exceptional circumstances)

Duration:
12 months for phase 1.
Phase 2 will offer a further 3 years of funding of around £3 million per project if key milestones under phase 1 are met

Eligibility:   

• Call is open to academic institutions without geographical restrictions.
• PI must have an internationally competitive research track record in drug design or development.

• More information about the program is available here
• Letter of Intent template is available here